Balchem Corp. 10-K Summary (Fiscal Year Ended Dec 31, 2002)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002, for Balchem Corporation, a Maryland-based developer and manufacturer of specialty performance ingredients for the food, feed, and medical sterilization industries. The Company operates through three segments: Specialty Products (ethylene oxide, propylene oxide, methyl chloride), Encapsulated/Nutritional Products (encapsulated ingredients for food and animal health), and Unencapsulated Feed Supplements (choline chloride for poultry and swine). The reporting period includes the full-year impact of a June 2001 acquisition of assets from DCV, Inc. and DuCoa L.P.
Key Financial Metrics
| Metric | 2002 | 2001 |
|---|---|---|
| Net Sales | $60,197,000 | $46,142,000 |
| Gross Profit | $23,310,000 | $17,926,000 |
| Gross Margin | 38.7% | 38.8% |
| Net Earnings | $7,416,000 | $5,110,000 |
| Diluted EPS | $1.50 | $1.05 |
| Operating Cash Flow | $10,114,000 | $3,222,000 |
| Total Assets | $53,298,000 | $44,477,000 |
| Long-Term Debt | $9,581,000 | $11,323,000 |
| Working Capital | $10,884,000 | $10,547,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30.5% to $60.2 million, driven primarily by a 52.9% surge in the Encapsulated/Nutritional Products segment ($28.0 million) and a 52.9% increase in the Unencapsulated Feed Supplements segment ($10.2 million, reflecting a full year of operations post-acquisition).
- Profitability: Net earnings rose 45.1% to $7.4 million. Earnings from operations increased to $12.2 million from $8.2 million.
- Cost Structure: Operating expenses increased 13.9% to $11.1 million due to higher advertising and personnel costs in sales, marketing, and R&D. However, operating expenses as a percentage of sales improved to 18.5% from 21.2%.
- Accounting Changes: The Company adopted SFAS No. 142 in 2002, ceasing the amortization of goodwill. This eliminated a $170,000 expense present in 2001.
- Capital Expenditures: Capital spending jumped to $10.0 million in 2002 (from $2.0 million in 2001) to expand facilities in Verona, Missouri, and lease new headquarters in New Hampton, NY.
Guidance, Outlook, and Risks
- Outlook: Management projects capital expenditures of approximately $2.4 million for 2003. The Company expects operations to generate sufficient cash flow to fund working capital and debt obligations.
- Regulatory Risks: The Company's ability to sell ethylene oxide depends on EPA re-registration, which is pending due to agency backlogs. While management expects success, a delay or denial could materially impact the Specialty Products segment. Additionally, the Verona facility was a former Superfund site; while remediation is deemed complete and the Company is indemnified, ongoing monitoring is required.
- Customer Concentration: One customer (Sterigenics) accounted for 9% of net sales in 2002. The loss of this customer could have a material adverse effect.
- Debt Covenants: The Company maintains a $13.5 million term loan (maturity May 2009) and a $3.0 million revolving credit facility. It was in compliance with all covenants as of year-end.
Investor Verification Checklist
- EPA Re-registration Status: Verify the current status of the ethylene oxide re-registration process with the EPA, as this is critical to the Specialty Products segment.
- Superfund Liability: Confirm that the indemnification agreements regarding the Verona facility's Superfund history remain valid and that no new environmental liabilities have emerged.
- Customer Concentration: Monitor the relationship with Sterigenics (9% of sales) and assess the risk of customer consolidation in the sterilization industry.
- Debt Servicing: Review the Company's ability to meet the $1.742 million annual principal payments on the term loan given the high capital expenditure cycle in 2002.
- Segment Margins: Analyze the trend in the Unencapsulated Feed Supplements segment, which reported an operating loss of $173,000 in 2002, to ensure it does not erode overall profitability.